Organovo bioprinter

L'Oreal USA and Organovo Holdings have announced a partnership pairing Organovo's proprietary NovoGen Bioprinting Platform with L'Oreal's U.S.-based global Technology Incubator for 3D printed skin research. This is the first application of Organovo's technology with the beauty industry.

"We developed our technology incubator to uncover disruptive innovations across industries that have the potential to transform the beauty business," said Guive Balooch, Global Vice President of L'Oreal's Technology Incubator. "Organovo has broken new ground with 3D bioprinting, an area that complements L'Oreal's pioneering work in the research and application of reconstructed skin for the past 30 years. Our partnership will not only bring about new advanced in vitro methods for evaluating product safety and performance, but the potential for where this new field of technology and research can take us is boundless."

Organovo's 3D bioprinting enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. The partnership is expected to involve the engineering of 3D printed skin tissue for product evaluation and other areas of advanced research.

"We are excited to be partnering with L'Oreal, whose leadership in the beauty industry is rooted in scientific innovation and a deep commitment to research and development," said Keith Murphy, Chairman and Chief Executive Officer at Organovo. "This partnership is a great next step to expand the applications of Organovo's 3-D bioprinting technology and to create value for both L'Oreal and Organovo by building new breakthroughs in skin modeling."

Loreal USA manages 30 beauty brands and has research, manufacturing and distribution facilities in 13 states, plus corporate headquarters in New York. Organovo Holdings designs and creates 3D human tissues for use in medical research, cosmetic and therapeutic applications. In April the company presented data on fully cellular, 3D bioprinted kidney tissue – a point of interest for researchers testing kidney toxicology. Based in San Diego, Calif., Organovo (ONVO) is listed on Nasdaq.